SFMMLKDZAWGSRC-PBYQXAPXSA-N
C34H30F6N4O5 — CID 56968953
Data last refreshed: (MolForge compound catalog, from PubChem)
About SFMMLKDZAWGSRC-PBYQXAPXSA-N
SFMMLKDZAWGSRC-PBYQXAPXSA-N (PubChem CID 56968953) has the molecular formula C34H30F6N4O5 and a molecular weight of 688.63 g/mol. Its IUPAC name is 5-[3-[6-(azetidin-1-yl)-2-[[(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl]methyl]-3-pyridinyl]-4-methoxyphenyl]-1-methylpyrrole-3-carboxylic acid.
Molecular Properties
| Compound Name | SFMMLKDZAWGSRC-PBYQXAPXSA-N |
|---|---|
| PubChem CID | 56968953 |
| Molecular Formula | C34H30F6N4O5 |
| Molecular Weight | 688.63 g/mol |
| Exact Mass | 688.21 |
| IUPAC Name | 5-[3-[6-(azetidin-1-yl)-2-[[(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl]methyl]-3-pyridinyl]-4-methoxyphenyl]-1-methylpyrrole-3-carboxylic acid |
| SMILES | COc1ccc(-c2cc(C(=O)O)cn2C)cc1-c1ccc(N2CCC2)nc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C |
| InChI | InChI=1S/C34H30F6N4O5/c1-18-30(20-11-22(33(35,36)37)15-23(12-20)34(38,39)40)49-32(47)44(18)17-26-24(6-8-29(41-26)43-9-4-10-43)25-13-19(5-7-28(25)48-3)27-14-21(31(45)46)16-42(27)2/h5-8,11-16,18,30H,4,9-10,17H2,1-3H3,(H,45,46)/t18-,30-/m0/s1 |
| InChIKey | SFMMLKDZAWGSRC-PBYQXAPXSA-N |
| XLogP | 7.79 |
| TPSA | 97.13 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 49 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 688.63 |
| LogP ≤ 5 | 7.79 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 56968953 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.